These past several months have been extremely exciting for ReceptoPharm as we continue to grow and progress with our clinical trials.

I’d like to take this opportunity to help clarify our most recent press release from April 11th, which discusses ReceptoPharm’s newest patent surrounding autoimmune diseases. As we mentioned in the press release, the ReceptoPharm patent describes a new method for treating autoimmune diseases by inducing the expression of interleukin 27 (IL-27) gene and is a continuation of an application we made some years ago.

There are a number of reasons why this patent is important to ReceptoPharm and its continued drug development. Primarily, this patent describes a novel mechanism for treating autoimmune diseases using ReceptoPharm’s lead drug candidate, RPI-78M revealing more detail on the drug’s mechanism of action. It is believed that RPI-78M is the first drug that can actually induce the expression of IL-27 in people with autoimmune diseases.

Furthermore, this patent precedes a similar patent from the multi-billion dollar biotechnology company, Genentech. Genentech’s patent application also describes a method for treating autoimmune diseases using IL-27, but where Genentech’s method discusses giving patients IL-27 directly, the ReceptoPharm patent discusses inducing IL-27 using RPI-78M. Being able to induce IL-27 rather than giving it directly to the patient may provide a significant advancement in the treatment process, as the administration of IL-27 may evoke unpleasant side-effects. To date, the side effect profile of RPI-78M is very good.

In summary, this patent helps build upon the foundation of ReceptoPharm’s drug discovery research. As ReceptoPharm continues to research treatments for autoimmune diseases, this patent will also help protect its method of treatment. And finally, the therapeutic approach described in the ReceptoPharm patent helps build credibility for the Company, which is especially important as we move through the clinical trial process.

Paul

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " A Brief Discussion of ReceptoPharm’s Newest Patent", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website